Results 111 to 120 of about 113,908 (219)

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle. [PDF]

Clin Cancer Res
Nyquist MD, Nelson PS.
europepmc   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia

The Prostate, EarlyView.
ABSTRACT Background Benign prostatic hyperplasia (BPH) leads to prostate enlargement and lower urinary tract symptoms that can resist treatment. A histologic hallmark of BPH is glandular epithelial hyperplasia with new ductal branching morphogenesis. The stromal inductive factors driving tissue morphogenesis may provide new therapeutic targets, but are
Anna S. Pollack, James D. Brooks, Jonathan R. Pollack   +2 more
wiley   +1 more source

Androgen Receptor Point Mutations: A Mechanism of Therapeutic Resistance and a Framework for Rational Drug Design. [PDF]

Cancers (Basel)
Colah A, Ferková S, Zhang H, Liu G, MacGillivray L, Boudreault PL, Ricke W.   +6 more
europepmc   +1 more source

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background For patients with unfavorable intermediate or high risk localized prostate cancer receiving definitive radiotherapy, androgen deprivation therapy reduces recurrence and improves survival but is underutilized due to toxicity concerns. Patients who forgo initial ADT may later require salvage ADT.
Jiaye Shen, Aaron J. Katz, Yahui Xie, Ronald C. Chen, Mutlay Sayan   +4 more
wiley   +1 more source

Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer. [PDF]

Oncol Rev
van de Weerdt EK, Duits AJ, Samson MJ, Schnog JB.   +3 more
europepmc   +1 more source

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Yuki Yoshikawa, Ryoichi Maenosono, Akihito Takeuchi, Kiyoshi Takahara, Seitetsu Sugiyama, Kazumasa Komura, Takafumi Yanagisawa, Wataru Fukuokaya, Takahiro Kimura, Kazutoshi Fujita   +14 more
wiley   +1 more source

Intermittent Fasting and Androgen Receptor Signaling in Prostate Cancer: Metabolic Crosstalk and Therapeutic Implications. [PDF]

Int J Mol Sci
Gromadzka G, Bendykowska M.
europepmc   +1 more source

Management of De Novo miN1 Prostate Cancer in the PSMA‐PET Era

The Prostate, EarlyView.
ABSTRACT Background Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is reshaping nodal staging in prostate cancer by detecting regional lymph node metastases with greater accuracy than conventional imaging. This has created a new cohort of patients with N1M0 disease detectable only on advanced imaging, raising important ...
Thomas McMaster, Caitlin Ying Ming Louey, Jordan Santucci, Chloe Hobson, David D. Chen, Niranjan Sathianathen, Joseph Ischia, Damien M. Bolton, Nathan Lawrentschuck, Declan G. Murphy, Shankar Siva, Marlon Perera   +11 more
wiley   +1 more source